Dublin, Jan. 13, 2017 -- Research and Markets has announced the addition of the "Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021" report to their offering.
The biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3%.
The global biosimilars market is segmented on the basis of product, manufacturing type, and application. Factors such as rising incidence of various diseases, increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars are expected to drive the growth of this market.
Emerging markets and new indications and patent expiry of biologic products has opened an array of opportunities for players in the biosimilars market. However, complexities in manufacturing and innovative strategies by biologic drug manufacturers are expected to restrain the growth of this market to a certain extent during the forecast period.
The key players in the biosimilars market include:
- Amgen Inc.
- Biocon Ltd.
- Celltrion Inc.
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche Ltd.
- Mylan Inc.
- Pfizer Inc.
- Samsung Bioepis
- Sandoz International Gmbh (A Division of Novartis International Ag)
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Biosimilars Market, by Type of Product
7 Biosimilars Market, by Type of Manufacturing
8 Biosimilars Market, by Application
9 Biosimilars Market, by Region
10 Competitive Landscape
11 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/kb6hn6/biosimilars
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 



